Drug delivery systems for the treatment of restenosis

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 17, Issue 3, 2000, Pages 249-284

  Chorny, Michael ^a   Fishbein, Ilia ^a   Golomb, Gershon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Controlled release; Drug delivery systems; Nanoparticles; Polymeric based drug delivery; Restenosis

Indexed keywords

3,5 DI TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; DRUG CARRIER; DRUG VEHICLE; ETHYLENE VINYL ACETATE COPOLYMER; LIPOSOME; MACROGOL; NANOPARTICLE; POLOXAMER; POLYANHYDRIDE; POLYGLACTIN; POLYLACTIC ACID; POLYMER; PROTEIN TYROSINE KINASE INHIBITOR; TYRPHOSTIN;

ANGIOPLASTY; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROTIC PLAQUE; BIOCOMPATIBILITY; CONTROLLED DRUG RELEASE; CORONARY ARTERY RECANALIZATION; DRUG DELIVERY SYSTEM; GENE TARGETING; HUMAN; NONHUMAN; POLYMERIZATION; RESTENOSIS; REVIEW; VALIDATION PROCESS;

EID: 0033918482     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevtherdrugcarriersyst.v17.i3.20     Document Type: Review

References (194)

1. Baim, D.S., Interventional catheterization techniques: Percutaneous transluminal balloon angioplasty, valvuloplasty and related procedures, in Heart Disease: A Textbook of Cardiovascular Medicine, Vol. 2, Braunwald, E., Ed., Philadelphia: Saunders, 1992, 1365.
2. Nobuyoshi, M., Kimura, T., and Ohishi, H., Restenosis after percutaneous transluminal coronary angioplasty: Pathologic observation in 20 patients, J. Am. Coll. Cardiol., 17, 433, 1991.
3. Topol, E.J., Ellis, S., Cosgrove, D., Bates, E., Muller, D., Schork, N., and Loop, F., Analysis of coronary angioplasty practice in the United States with an insurance-claims database, Circulation, 87, 1489, 1993.
4. Schwartz, R.S., Neointima and arterial injury: Dogs, rats, pigs, and more, Lab. Invest., 71, 789, 1994.
5. Schwartz, S.M., deBlois, D., and O'Brien, E.R.M., The intima. Soil for atherosclerosis and restenosis, Circ. Res., 77, 445, 1995.
6. Nikol, S., Huehns, T.Y., and Hofling, B., Molecular biology and postangioplasty restenosis, Atherosclerosis, 123, 17, 1996.
7. Bauters, C. and Isner, J.M., The biology of restenosis, Progr. Cardiovasc. Dis., 40, 107, 1997.
8. Faxon, D.P., Coats, W., and Currier, J., Remodeling of the coronary artery after vascular injury, Progr. Cardiovasc. Dis., 40, 129, 1997.
9. Shi, Y., Pieniek, M., Fard, A., O'Brien, J., Mannion, J.D., and Zalewski, A., Adventitial remodeling after coronary arterial injury, Circulation, 93, 340, 1996.
10. Hafizi, S., Chester, A.H., and Yacoub, M.H., Molecular mechanisms of vascular smooth muscle cells growth, Curr. Opin. Cardiol., 12, 495, 1997.
11. Lindner, V., Olson, N.E., Clowes, A. W., and Reidy, M.A., Inhibition of smooth muscle cell proliferation in injured rat arteries Interaction of heparin with basic fibroblast growth factor, J. Clin. Invest., 90, 2044, 1992.
12. Lindner, V., Reidy, M.A., and Ross, R., Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries, J. Clin. Invest., 85, 2004, 1990.
13. Lindner, V., Lappi, D.A., Baird, A., Majack, R.A., and Reidy, M.A., Role of basic fibroblast growth factor in vascular lesion formation, Circ. Res., 68, 106, 1991.
14. Lindner, V. and Reidy, M.A., Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor, Proc. Natl. Acad. Sci. USA, 88, 3739, 1991.
15. Ferns, G.A.A., Raines, E.W., Sprugel, K.H., Motani, A.S., Reidy, M.A., and Ross, R., Inhibition of neointimal smooth muscle accumulation after angioplasty by antibody to PDGF, Science, 253, 1129, 1991.
16. Hart, C.E. and Clowes, A.W., Platelet-derived growth factor and arterial response to injury, Circulation, 95, 555, 1997.
17. Jawien, A., Bowen-Pope, D.F., Linder, V., Schwartz, S.M., and Clowes, A.W., Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty, J. Clin. Invest., 89, 507, 1992.
18. Schlessinger, J., Cellular signaling by receptor tyrosine kinases, in The Harvey Lectures, Vol. 89, 1995.
19. Hunter, T., Tyrosine phosphorylation: past, present and future, Biochem. Soc. Trans., 24, 307, 1996.
20. Linseman, D.A., Benjamin, C. W., and Jones, D.A., Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells, J. Biol. Chem., 270, 12563, 1995.
21. Berk, B.C. and Corson, M.A., Angiotensin II signal transduction in vascular smooth muscle; Role of tyrosine kinases, Circ. Res., 80, 607, 1997.
22. Levitzki, A., Tyrphostins: Tyrosine kinase blockers as novel antiproliferelative agents and dissectors of signal transduction, FASEB J., 6, 3275, 1992.
23. Levitzki, A. and Gazit, A., Tyrosine kinase inhibition: An approach to drug development, Science, 267, 1782, 1995.
24. Levitzki, A., Signal transduction interception as a novel approach to disease management, Ann. NY Acad. Sci., 363, 1995.
25. Levitzki, A., Targeting signal transduction for disease therapy, Curr. Opin. Cell Biol., 8, 239, 1996.
26. Bilder, G.E., Krawiec, J.A., McVety, K., Gazit, A., Gilon, C., Lyall, R., Zilberstein, A., Levitzki, A., Perrone, M.H., and Schreiber, A.B., Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells, Am. J. Physiol., 260, C721, 1991.
27. Shimokado, K., Umezawa, K., and Ogata, J., Tyrosine kinase inhibitors inhibit multiple steps of the cell cycle of vascular smooth muscle cells, Exp. Cell Res., 220, 266, 1995.
28. Shimokado, K., Yokota, T., Kosaka, C., Zen, K., Sasaguri, T., Masuda, J., and Ogata, J., Protein tyrosine kinase inhibitors inhibit both proliferation and chemotaxis of vascular smooth muscle cells, Ann. NY Acad. Sci., 748, 171, 1995.
29. Shimokado, K., Yokota, T., Umezawa, K., Sasaguri, T., and Ogata, J., Protein tyrosine kinase inhibitors inhibit chemotaxis of vascular smooth muscle cells, Arterioscler. Thromb., 14, 973, 1994.
30. Huynh, T.T.T., Davies, M.G., Barber, L., Svendsen, E., and Hagen, P.-O., Local inhibition of tyrosine kinase activity markedly attenuates the development of intimal hyperplasia in experimental vein grafts, J. Surg. Res., 77, 104, 1998.
31. Myllarniemi, M., Calderon, L., Lemstrom, K., Buchdunger, E., and Hayry, P., Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation, FASEB J., 11, 1119, 1997.
32. Ito, A., Shimokawa, H., Kadokami, T., Fukumoto, Y., Owada, M.K., Shiraishi, T., Nakaike, R., Takayanagi, T., Egashira, K., and Takeshita, A., Tyrosine kinase inhibitor suppressess coronary arteriosclerotic changes and vasospastic responses induced by chronic treatment with interleukin-1ß in pigs in vivo, J. Clin. Invest., 96, 1288, 1995.
33. Golomb, G., Fishbein, I., Banai, S., Mishaly, D., Moscovitz, D., Gertz, S.D., Gazit, A., Poradosu, E., and Levitzki, A., Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model, Atherosclerosis, 125, 171, 1996.
34. Fukumoto, Y., Shimokawa, H., Kozai, T., Kadokami, T., Kuwata, K., Owada, M.K., Shiraishi, T., Kuga, T., Egashira, K., and Takeshita, A., Tyrosine kinase inhibitor suppresses the (re)stenotic changes of the coronary artery after balloon injury in pigs, Cardiovasc. Res., 32, 1131, 1996.
35. Herrman, J.P.R., Hermans, W.R.M., Vos, J., and Serruys, P.W., Pharmacological approaches to the prevention of restenosis following angioplasty: Part I, Drugs, 46, 18, 1993.
36. Herrman, J.P.R., Hermans, W.R.M., Vos, J., and Serruys, P.W., Pharmacological approaches to the prevention of restenosis following angioplasty: Part II, Drugs, 46, 249, 1993.
37. Landzberg, B.R., Frishman, W.H., and Lerrick, K., Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures, Progr. Cardiovasc. Dis., XXXIX, 361, 1997.
38. Lefkovits, J. and Tolol, EJ., Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention, Progr. Cardiovasc. Dis., 40, 141, 1997.
39. Edelman, E.R., Simons, M., Sirois, M.G., and Rosenberg, R.D., C-myc in vasculoproliferative disease, Circ. Res., 76, 176, 1995.
40. Lincoff, A.M., Topol, E.J., and Ellis, S.G., Local drug delivery in the prevention of restenosis. Fact, fancy, and future, Circulation, 90, 2070, 1994.
41. Riessen, R. and Isner, J.M., Prospects for site-specific delivery of pharmacologic and molecular therapies J. Am. Coll. Cardiol., 23, 1234, 1994.
42. McKenna, C.J., Hohnes, D.R., and Schwartz. R.S., Novel stents for the prevention of restenosis, Trends Cardiovasc. Med., 7, 245, 1997.
43. Muller, D.W.M. and Topol, E.J., Implantable devices in the coronary artery - From metal to genes, Trends Cardiovasc. Med., 1, 225, 1991.
44. Belli, G., Ellis, S.G., and Topol, E.J., Stenting for ischemic heart disease, Progr. Cardiovasc. Dis., 40, 159, 1997.
45. Kumamoto, M., Nakasima, Y., and Sueishi, K., Intimal neovascularization in human coronary atherosclerosis: Its origin and pathophysiological significance, Hum. Pathol, 26, 450, 1995.
46. Wolinsky, H. and Glagov, S., Nature of species differences in the medial distribution of aortic vasa vasorum in mammals, Circ. Res., 20, 409, 1967.
47. Shi, Y., O'Brien, J.E., Fard, A., Mannion, J.D., Wang, D., and Zalewski, A., Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries, Circulation, 94, 1655, 1996.
48. Wilcox, J.N., Cipolla, G.D., Martin, F.H., Simonet, L., Dunn, B., Ross, C.E., and Scott, N.A., Contribution of adventitial myofibroblasts to vascular remodeling and lesion formation after experimental angioplasty in pig coronary arteries, Ann. NY Acad. Sci., 811, 437, 1997.
49. Faxon, D.P. and Currier, J.W., Remodeling after angioplasty: A new target for prevention, in Atherosclerosis X, Woodfort, F.P., Davignon, J., and Sniderman, A., Eds., Elsevier Science, 1995, 685.
50. Lovich, M.A., Brown, L., and Edelman, E.R., Drug clearance and arterial uptake after local perivascular delivery to the rat carotid artery, J. Am. Coll. Cardiol., 29, 1645, 1997.
51. Ip, J.H., Faster, V., Badimon, L., Badimon, J., Taubman, M.B., and Chesebro, J.H., Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation, J. Am. Coll. Cardiol., 15, 1667, 1990.
52. Edelman, E.R., Adams, D.H., and Karnovsky, M.J., Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury, Proc. Natl. Acad. Sci. USA, 87, 3773, 1990.
53. Edelman, E.R., Nugent, M.A., Smith, L.T., and Karnovsky, M.J., Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries, J. Clin. Invest., 89, 465, 1992.
54. Edelman, E.R., Nugent, M.A., and Karnovsky, M.J., Perivascular and intravenous administration of basic fibroblast growth factor: Vascular and solid organ deposition, Proc. Natl. Acad. Sci. USA, 90, 1513, 1993.
55. Edelman, E.R. and Karnovsky, M.J., Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis, Circulation, 89, 770, 1994.
56. Fishbein , I., Waltenberger, J., Banai, S., Rabinovich, L., Chorny, M., Levitzki, A., Gazit, A., Huber, R., Gertz, S.D., and Golomb, G., Local delivery of PDGF receptor-specific tyrphostin inhibits neointimal formation in rats, Arterioscler. Thromb. Vasc. Biol., in press.
57. Golomb, G., Mayberg, M., and Domb, AJ., Polymeric perivascular delivery systems, in Polymeric site-specific pharmacotherapy, Domb, AJ., Ed., New York: Wiley, 1994, 205.
58. Edelman, E.R., Pukac, L.A., and Karnovsky, M.J., Protamine and protamine-insulins exacerbate the vascular response to injury, J. Clin. Invest., 91, 2308, 1993.
59. Golomb, G. and Fishbein, I., Tyrphostins, inhibitors of protein tyrosine kinase, in restenosis, Adv. Drug Deliv. Rev., 24, 53, 1997.
60. Mishaly, D., Fishbein, I., Moscovitz, D., and Golomb, G., Site-specific delivery of colchicine in rat carotid artery model of restenosis, J. Controlled Rel., 45, 65, 1997.
61. Brauner, R., Laks, H., Drinkwater, D. CJ., Chaudhuri, G., Shvarts, O., Drake, T., Bhuta, S., Mishaly, D., Fishbein, I., and Golomb, G., Controlled periadventitial administration of verapamil inhibits neointimal smooth muscle cell proliferation and ameliorates vasomotor abnormalities in experimental vein bypass grafts, J. Thorac. Cardiovasc. Surg., 114, 53, 1997.
62. Sirois, M.G., Simons, M., and Edelman, E.R., Antisense oligonucleotide inhibition of PDGF-ß receptor subunit expression directs suppression of intimal thickening, Circulation, 95, 669, 1997.
63. Villa, A.E., Guzman, L.A., Golomb, G., Levy, R.J., and Topol, E.J., Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty, J. Clin. Invest., 93, 1243, 1994.
64. Muller, D.W.M., Golomb, G., Gordon, D., and Levy, R.J., Site-specific dexamethasone delivery for the prevention of neointimal thickening after vascular stent implantation, Coronary Artery Dis., 5, 435, 1994.
65. Muller, D.W., Gordon, D., Topol, E.J., Levy, R.J., and Golomb, G., Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting, Am. Heart J., 131, 211, 1996.
66. Voisard, R., Seitzer, U., Baur, R., Dartsch, P.C., Osterhues, P.C., Hoher, M., and Hornbach, V., A prescreening system for potential antiproliferative agents: Implications for local treatment strategies of postangioplasty restenosis, Int. J. Cardiol., 51, 15, 1995.
67. Rabinovich, L., Charaterization of in vitro tissue culture models used in the evaluation of potential treatments for restenosis, M.Sc. Thesis, The Hebrew University of Jerusalem, Jerusalem, 1999.
68. Teomim, D., Fishbein, I., Golomb, G., Orloff, L., Mayberg, M., and Domb, AJ., Perivascular delivery of heparin for the reduction of smooth muscle cell proliferation after endothelial injury, J. Controlled Rel., 60, 129, 1999.
69. Ishizaka, N., Kurokawa, K., Taguchi, J., Miki, K., and Ohno, M., Inhibitory effect of a single local probucol administration on neointimal formation in balloon-injured rat carotid artery, Atherosclerosis, 118, 53, 1995.
70. Bennett, M.R., Anglin, S., McEwan, J.R., Jagoe, R., Newby, A.C., and Evan, G.I., Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides, J. Clin. Invest., 93, 820, 1994.
71. Castier, Y., Chemla, E., Nierat, J., Heudens, D., M A, Rainoch, C., Bruneval, P., Carpentier, A., and Fabiani, J.N., The activity of c-myb antisense oligonucleotide to prevent intimal hyperplasia is nonspecific, J. Cardiovasc. Surg., 39, 1, 1998.
72. Villa, A.E., Guzman, L.A., Poptic, E.J., Labhasetwar, V., D'Souza, S., Farrell, C.L., Plow, E.F., Levy, R.J., DiCorleto, P.E., and Topol, E.J., Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury, Circ. Res., 76, 505, 1995.
73. Abe, J.-i., Zhou, W., Taguchi, J.-i., Takuwa, N., Miki, K., Okazaki, H., Kurokawa, K., Kumada, M., and Takuwa, Y., Suppression of neointimal smooth muscle cell accumulation in vivo by antisense CDC2 and CDK2 oligonucleotides in rat carotid artery, Biochem. Biophys. Res. Commun., 198, 16, 1994.
74. Slepian, M.J., Masia, S.P., Dehdashti, B., Fritz, A., and Whitesell, L., ß3-integrins rather than ß1 -integrins dominate integrin-matrix interactions involved in postinjury smooth muscle cell migration, Circulation, 97, 1818, 1998.
75. Indolfi, C., Avvedimento, E.V., Rapacciuolo, A., Di Lorenzo, E., Esposito, G., Stabile, E., Feliciello, A., Mele, E., Giuliano, P., Condorelli, G.L., and Chiariello, M., Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo, Nature Med., 1, 541, 1995.
76. Wang, W., Chen, H.J., Schwartz, A., Cannon, P.J., Stein, C.A., and Rabbani, L.E., Sequence independent inhibition of in vitro smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides, J. Clin. Invest., 98, 443, 1996.
77. Desai, S.D. and Blanchard, J., Evaluation of pluronic F127-based sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model, J. Pharm. Sci., 87, 1190, 1998.
78. Gottsauner-Wolf, M., Jang, Y., Lincoff, A. M., Cohen J. L., Labhasetwar, V., Poptic, E.J., Forudi, F., Guzman, L.A., DiCorleto, P.E., Levy, R.J., Topol, EJ., and Ellis, S.G., Influence of local delivery of the protein tyrosine kinase receptor inhibitor tyrphostin-47 on smooth-muscle cell proliferation in a rat carotid balloon-injury model, Am. Heart J., 133, 329,1997.
79. Nathan, A., Nugent, M.A., and Edelman, E.R., Tissue engineered perivascular endothe-lial cell implants regulate vascular injury, Proc. Natl. Acad. Sci. USA, 92, 8130,1995.
80. Han, R.O., Ettenson, D.S., Koo, E.W.Y., and Edelman, E.E., Heparin/heparan sulfate chelation inhibits control of vascular repair by tissue-engineered endothelial cells, Am. J. Physiol.,273,H2586,1997.
81. Nugent, H.M., Rogeirs, C., and Edelman, E.R., Endothelial implants inhibit intimai hy-perplasia after porcine angioplasty, Circ. Res., 84,384,1999.
82. Rome,J.J., Shayatni,V.,Flugelman, M.Y.,Newman, K.D.,Färb,A.,Virmani,R.,and Dichek, D.A., Anatomic barriers influence the distribution of in vivo gene transfer into the arterial wall. Modeling with microscopic tracer particles and verification with a recombinant aden-oviral vector, Arteriosder. Thromb., 14,148,1994.
83. Wilensky, R.L., March, K.L., and Hathaway, D.R., Direct intraarterial wall injection of microparticles via a catheter: A potential drug delivery strategy following angioplasty, Am. Heart J., 22,1136,1991.
84. Dev,V.,Eigler,N.,Fishbein,M.C.,Tian,Y.,Hickey,A.,Rechavia,E.,Forrester,J. S.,and Litvack, F., Sustained local drug delivery to the arterial wall via biodegradable niicros-pheres, Catheter. Cardivvasc. Diagn., 41,324,1997.
85. Robinson,K.A.,Chronos,N.A.F.,Schieffer,E.,Palmer,S.J., Cipolla, G.D.,Milner,P.G., Walsh, R.G.. and King, S.B.I., Pharmacokinetics and tissue localization of antisense oligonu-cleotides in balloon-injured pig coronary arteries after local delivery with an iontophoretic balloon catheter, Catheter. Cardiovasc. Diagn., 41,354,1997.
86. Mitchel,J.F.,Fram,D.B.,Palme,D.,Foster,R.,Hirst,J.A.,Azrin,M.A.,Bow,L.M., Eldin, A.M., Waters, D.D., and McKay, R.G., Enhanced intracoronary thrombolysis with uro-kinase using a novel, local drug delivery system, in vitro, in vivo, and in clinical studies, Circulation, 91,785,1995.
87. Asahara, T., Banters, C., Pastore, C., Kearney, M., Rossow, S., Bunting, S., Ferrara, N., Symes ,J.F., and Isner,J.M.,Local delivery of vascular endothelial growth factor accelara tes reeiidolhelialization and attenuates intimai hyperplasia in balloon-injured rat carotid artery, Circulation, 91, 2793, 1995.
88. Brown, D.M., Kania, N.M., Choi, E.T., Landen, L.A., Pasia, E.N., Wun, T.-C., and Khouri, R.K., Local irrigation with tissue factor pathway inhibitor inhibits intimai hyper-plasia induced by arterial interventions, Arch. Surg., 131,1086,1996.
89. Liu,M.W., Lin,S.-J.,and Chen, Y.-L., Local alcohol delivery may reduce phenotype con-version of smooth muscle cells and neointimal formation in rabbit iliac arteries after balloon injury, Atherosclerosis, 127,221,1996.
90. Liu, M. W., Anderson, P.G., LuoJ.F., and Roubin, G.S., Local delivery of ethanol inhibits intimai hyperplasia in pig coronary arteries after balloon injury, Circulation, 96,2295,1997.
91. Marks, D.S., Vita,J,A., Foils,J.D., KeaneyJ.F., Welch, G.N., and Loscalzo,J., Inhibi-tion of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide, J. Clin. Invest., 96,2630,1995.
92. Morishita, R., Gibbons, G.H., Ellison, K.E.,Nakajima, M., Zhang, L., Kaneda, Y., Ogi-hara, T., and Dxau, V.J., Single intraluminal delivery of antisense cdc2 kinase and prolif-erating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hy-perplasia, Proc. Natl. Acad. Sci. USA, 90, 8474,1993.
93. 1 and CDC 2 kinase) in the vessel wall in vivo: Enhanced therapeutic utility for restenosis by HVJ-liposome delivery, Gene, 149, 13, 1994.
94. Morishita, R., Gibbons, G.H., Ellison, K.E., Lee, W., Zhang, L.,Yu, H., Kaneda, Y., Ogihara, T., and Dzau, V.J., Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme, J. Clin. Invest., 94, 978, 1994.
95. Morishita, R., Gibbons, G.H., Horiuchi, M., Ellison, K.E., Nakajima, M., Zhang, L., Kaneda, Y., Ogihara, T., and Dzau, V.J., A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle cell proliferation in vivo, Proc. Natl. Acad. Sci. USA, 92, 5855, 1995.
96. Suzuki, J.-i., Isobe, M., Morishita, R., Aoki, M., Horie, S., Okubo,Y., Kaneda, Y., Sawa, Y., Matsuda, H., Ogihara, T., and Sekiguchi, M., Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide, Nature Med., 3, 900, 1997.
97. von der Leyen, H.E., Gibbons, G.H., Morishita, R., Lewis, N.P., Zhang, L., Nakajima, M., Kaneda, Y., Cooke, J.P., and Dzau, V.J., Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene, Proc. Natl. Acad. Sci. USA, 92, 1137, 1995.
98. Zhu, N.L., Wu, L., Liu, P.X., Gordon, E.M., Anderson, W.F., Starnes, W.A., and Hall, F.L., Downregulation of cyclin Gl expression by retrovirus-mediated antisense gene trans fer inhibits vascular smooth muscle cell proliferation and neointima formation, Circulation, 96, 628, 1997.
99. Baek, S. and March, K.L., Gene therapy for restenosis. Getting nearer the heart of the matter, Circ. Res., 82, 295, 1998.
100. Ueno, H., Yamamoto, H., Ito, S,å, Li, J.-J., and Takeshita, A., Adenovirus-mediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo, Arterioscler. Thromb. Vasc. Biol., 17, 898, 1997.
101. Harrell, R.L., Rajanayagam, M.A.S., Doanes, A.M., Guzman, R.J., Hirschowitz, E.A., Crystal, R.G., Epstein, S.E., and Finkel, T., Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase, Circulation, 96, 621, 1997.
102. Guzman, R.J., Hirschowitz, E.A., Brody, S.L., Crystal, R.J., Epstein, S.E., and Finkel, T., In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene, Proc. Natl. Acad, Sci. USA, 91, 10732, 1994.
103. Steg, P.G., Tahlil, Q., Aubailly, N., Caillaud, J.-M., Dedieu, J.-F., Berthelot, K.,Le Roux, A., Feldman, L., Perricaudet, M., P and Branellec, D., Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy, Circulation, 96, 408, 1997.
104. Chang, M.W., Barr, E., Lu, M.M., Barton, K., and Leiden, J.M., Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty, J. Clin. Invest., 96, 2260, 1995.
105. kip1, an inhibitor of neointima formation in the rat carotid artery, J. Clin. Invest., 99, 2334, 1997.
106. Scheinman, M., Ascher, E., Levi, G.S., Hingorani, A., Shirazian, D., and Seth, P., Gene transfer to the injured rat carotid artery decreases neointimal formation, J. Vasc. Surg., 29, 360, 1999.
107. Sata, M., Perlman, H., Muruve, D.A., Silver, M., Ikebe, M., Libermann, T.A., Oettgen, P., and Walsh, K., Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T-cell response, Proc. Natl. Acad. Sci. USA, 95, 1213, 1998.
108. Ueno, H., Haruno, A., Morisaki, N., Furuya, M., Kangawa, K., Takeshita, A., and Sayto, Y., Local expression of C-type natriuretic peptide markedly suppresses neointimal formation in rat injured arteries through an autocrine/paracrine loop, Circulation, 96, 2272, 1997.
109. Smith, R.C., Wills, K.N., Antelman, D., Perlman, H., Truong, L.N., Krasinski, K., and Walsh, K., Adenoviral constructs encoding phosphorylation-competent full-length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation, Circulation, 96, 1899, 1997.
110. Chang, M.W., Barr, E., Seltzer, J., Jiang, Y.-Q., Nabel, G.J., Nabel, E.G., Parmacek, M.S., and Leiden, J.M., Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product, Science, 267, 518, 1995.
111. Maillard, L., Van Bellle, E., Smith, R.C., Le Roux, A., Denefle, P., Steg, G., Barry, J.J., Branellec, D., Isner, J.M., and Walsh, K., Percutaneous delivery of the gax gene inhibits vessel stenosis in a rabbit model of balloon angioplasty, Cardiovasc. Res., 35, 536, 1997.
112. Rade, J.J., Schulick, A.H., Virmani, R., and Dichek, D.A., Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury, Nature Med., 2, 293, 1996.
113. Libby, P. and Tanaka, H., The molecular bases of restenosis, Progr. Cardiovasc. Dis., 40, 97, 1997.
114. Bjorkerud, S. and Bjorkerud, B., Lipoproteins are major and primary mitogens and growth promoters for human arterial smooth muscle cells and lung fibroblasts in vitro, Arterioscler. Thromb., 14, 288, 1994.
115. Fingerle, J., Johnson, R., Clowes, A. W., Majesky, M. W., and Reidy, M. A., Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery, Proc. Natl. Acad. Sci. USA, 86, 8412, 1989.
116. West, J.L. and Hubbel, J.A., Separation of the arterial wall from blood contact using hydrogel barriers reduces intimal thickening after balloon injury in the rat: The roles of medial and luminal factors in arterial healing, Proc. Natl. Acad. Sci., 93, 13188, 1996.
117. Slepian, M.J. and Hubbell, J.A., Polymeric endoluminal gel paving: Hydrogel systems for local barrier creation and site-specific drug delivery, Adv. Drug Deliv. Rev., 24, 11, 1997.
118. Zarge, J.I., Huang, P., Husak, V., Kim, D.U., Haudenschild, C.C., Nord, R.M., and Greisler, H.P., Fibrin glue containing fibroblast growth factor type 1 and heparin with autologous endothelial cells reduces intimai hyperplasia in a canine carotid artery balloon injury model, J. Vasc. Surg., 25, 840, 1997.
119. Valero, F., Hamon, M., Fournier, C., Meurice, T., Flautre, B., Van Belle, E., Lablanche, J.-M., Gosselin, B., Bauters, C., and Bertrand, M., Intramural injection of biodegradable microspheres as a local drug-delivery system to inhibit neointimal thickening in a rabbit model of balloon angioplasty, J. Cardiovasc. Pharmacol., 31, 513, 1998.
120. Nasser, T.K., Wilensky, R.L., Mehdi, K., and March, K.L., Microparticle deposition in periarterial microvasculature and intraluminal dissections after porous balloon delivery into atherosclerotic vessels: Quantification and localization by confocal scanning laser microscopy, Am. Heart J., 131, 892, 1996.
121. Labhasetwar, V., Song, C., Humphrey, W., Shebuski, R., and Levy, R.J., Arterial uptake of biodegradable narioparticles: Effect of surface modifications, J. Pharm. Sci, 87, 1229, 1998.
122. Labhasetwar, V., Song, C., and Levy, R.J., Nanoparticle drug delivery systems for restenosis, Adv. Drug Deliv. Rev., 24, 63-85, 1997.
123. Guzman, L.A., Labhasetwar, V., Song, C., Jang, Y., Lincoff, A.M., Levy, R., and Topol, E.J., Local intraluminal infusion of biodegradable polymeric nanoparticles: A novel approach for prolonged drug delivery after balloon angioplasty, Circulation, 94, 1441, 1996.
124. Fishbein, I., Chorny, M., Rabinovich, L., Banai, S., Levitzki, A., Gazit, A., Gertz, S.D., Gati, I., and Golomb, G., Nanoparticulate delivery system of the tyrphostin for the treatment of restenosis, J. Controlled Rel, 65, 221, 2000.
125. Gradus-Pizlo, I, Wilenski, R.L., March, K.L., Fineberg, N., Michaels, M., Sandusky, G.E., and Hathaway, D.R., Local delivery of biodegradable microparticles containing colchicine or a colchicine analogue: Effects on restenosis and implications for catheterbased drug delivery, J. Am. Coll. Cardiol., 26, 1549, 1995.
126. Humphrey, W.R., Erickson, L.A., Simmons, C.A., Northrup, J.L., Wishka, D.G., Morris, J., Labhasetwar, V., Song, C., Levy, R.J., and Shebuski, R.J., The effect of intramural delivery of polymeric nanoparticles loaded with antiproliferative 2-aminochrome U-86983 on neointimal hyperplasia development in balloon-injured porcine coronary artery, Adv. Drug Deliv. Rev., 24, 87, 1997.
127. Holmes, D.R., Camrud, A.R., Jorgenson, M.A., Edwards, W.D., and Schwartz, R.S., Polymeric stenting in the porcine coronary artery model: Differential outcome of exogenous fibrin sleeves versus polyurethane-coated stents, J. Am. Coll. Cardiol., 24(2), 525, 1994.
128. Slepian, M.J., Polymeric endoluminal gel paving: Therapeutic hydrogel barriers and sustained drug delivery depots for local arterial wall biomanipulation, Sem. Interv. Cardiol., 1(1), 103, 1996.
129. Kipshidze, N., Baker, J.E., and Nikolaychik, V., Fibrin coated stents as an improved vehicle for endothelial cell seeding, Circulation, 90 (Suppl I), 1-597, 1994.
130. Van Belle, E., Maillard, L., Tio, F.O., and Isner, J.M., Accelerated endothelialization by local delivery of recombinant human vascular endothelial growth factor reduces in-stent intimal formation, Biochem. Biophys. Res. Commun., 235, 311, 1997.
131. Van Belle, E., Tio, F.O., Couffinhal, T., Maillard, L., Passeri, J., and Isner, J.M., Stent endothelization: Time course, impact of local catheter delivery, feasibility of recombinant protein administration, and response to cytokine expedition, Circulation, 95, 438, 1997.
132. Aggarwal, R.K., Ireland, D.C., Azrin, M.A., Ezekowitz, M.D., de Bono, D.P., and Gershlick, A.H., Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor antibody, Circulation, 94, 3311, 1996.
133. Lincoff, A.M., Furst, J.G., Ellis, S.G., Tuch, R.J., and Topol, E.J., Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model, J. Am. Coll. Cardiol., 29, 808, 1997.
134. Topol, E.J. and Serruys, P.W., Frontiers ininterventionalcardiology, Circulation, 98, 1802, 1998.
135. Yamawaki, T., Shimokawa, H., Kozai, T., Miyata, K., Higo, T., Tanaka, E., Egashira, K., Shiraishi, T., Tamai, H., Igaki, K., and Takeshita, A., Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo, J. Am. Coll. Cardiol., 32, 780, 1998.
136. van der Giessen, W.J., Lincoff, A.M., Schwartz, R.S., van Beusekom, H.M.M., Serruys, P. W., Holmes, D.R., Ellis, S.G., and Topol, E.J., Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries, Circulation, 94, 1690, 1996.
137. Mattar, S.G., Hanson, S.R., Pierce, G.F., Chen, C., Hughes, J.D., Cook, J.E., Shen, C., Noe, B.A., Suwyn, C.R., Scott, J.R., and Lumsden, A.B., Local infusion of FGF-saporin reduces intimal hyperplasia, J. Surg. Res., 60, 339, 1996.
138. Pastore, C J., Isner, J,M., Bachc, P.A., Kearney, M., and Pickering, J.G., Epidermal growth factor receptor-targeted cytotoxin inhibits neointimal hyperplasia in vivo: Results of local versus systemic administration, Circ. Res., 77, 519, 1995.
139. Nagae, T., Louie, A.Y., Aizawa, K., Ishimaru, S., and Wilson, S.E., Selective targeting and photodynamic destruction of intimal hyperplasia by scavenger-receptor mediated protein-chlorin e6 conjugates, J. Cardiovasc. Surg., 39, 709, 1998.
140. Spragg, D.D., Alford, D.R., Greferath, R., Larsen, C.E., K-D, L., Gurtner, G.C., Cybulsky, M.I., Tosi, P.F., Nicolau, C., and Gimbrone, M.A., Immunotargeting of liposomes to activated vascular endothelial cells: A strategy for site-selective delivery in the cardiovascular system, Proc. Natl. Acad. Sci. USA, 94, 8795, 1997.
141. Hillis, G.S. and Flapan, A.D., Cell adhesion molecules in cardiovascular disease: A clinical perspective, Heart, 79, 429, 1998.
142. Giuffre, L., Cordey, A.-S., Monai, N., Tardy, Y., Schapira, M., and Spertini, O., Monocyte adhesion to activated aortic endothelium: Role of L-selectin and heparane sulfate proteoglycans, J. Cell Biol., 136, 945, 1997.
143. Wickham, T.J., Haskard, D., Segal, D., and Kovesdi, I, Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation, Cancer Immunol. Immunother., 45, 149, 1997.
144. Atochina, E.N., Balyasnikova, I., Danilov, S.M., Graiger, D.N., Fisher, A.B., and Muzykantov, V.R., Immunotargeting of catalase to ACE or ICAM-1 protects perfused rat lungs against oxidative stress, Am. J. Physiol., 275, L806, 1998.
145. Muzykantov, V.R., Immunotargeting of drugs to the pulmonary vascular endothelium as a therapeutic strategy, Pathophysiology, 5, 15, 1998.
146. Muzykantov, V.R., Barnathan, E.S., Atochina, E.N., Kuo, A., Danilov, S.M., and Fisher, A.B.,Targeting of antibody-conjugated plasminogen activators to the pulmonary vasculature, J. Pharm. Exp. Ther., 279, 1026, 1996.
147. Muzykantov, V.R., Christofidou-Solomidou, M., Balyasnikova, I., Harshaw, D.W., Schultz, L., Fisher, A.B., and Albelda, S.M., Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): A strategy for vascular immunotargeting of drugs, Proc. Natl. Acad. Sci. USA, 96, 2379, 1999.
148. Lijnen, H.R., Van Hoef, B., Lupu, F., Moons, L., Carmeliet, P., and Collen, D., Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system gemes, Arterioscler. Thromb. Vasc. Biol., 18, 1035, 1998.
149. Bochaton-Piallat, M.-L., Gabbiani, G., and Pepper, M.S., Plasminogen activator expression in rat arterial smooth muscle cells depends on their phenotype and is modulated by cytokines, Circ. Res., 82, 1086, 1998.
150. Herbert, J.M., Lamarche, I., and Carmeliet, P., Urokinase and tissue-type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet-derived growth factor for vascular smooth muscle cells, J. Biol. Chem., 272, 23585, 1997.
151. Plow, E.F. and D'Souza, S.E., A role for intercellular adhesion molecule-1 in restenosis, Circulation, 95, 1335, 1997.
152. Yasukawa, H., Imaizumi, T., Matsuoka, H., Nakashima, A., and Morimatsu, M., Inhibition of intimal hyperplasia after balloon injury by antibodies to intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1, Circulation, 95, 1515, 1997.
153. Sirois, M.G., Simons, M., Kuter, D.J., Rosenberg, R.D., and Edelman, E.R., Rat arterial wall retains myointimal hyperplastic potential long after arterial injury, Circulation, 96, 1291, 1997.
154. Forssen, E. and Willis, M., Ligand-targeted liposomes, Adv. Drug Deliv. Rev., 29, 249, 1998.
155. Labhasetwar, V., Chen, B., Muller, D.W.M., Bonadio, J., Ciftci, K., March, K., and Levy, R.J., Gene-based therapies for restenosis, Adv. Drug Deliv. Rev., 24, 109, 1997.
156. Ammoury, N., Dubrasquet, M., Fessi, H., Devissaguet, J.P., Puisieux, F., and Benita, S., Indomethacin-loaded poly(d,l-lactide) nanocapsules: Protection from gastrointestinal ulcerations and anti-inflammatory activity evaluation in rats, Clin. Mater., 13, 121, 1993.
157. Bonduelle, S., Foucher, C., Leroux, J.C., Chouinard, F., Cadieux, C., and Linaerts, V., Association of cyclosporin to isohexylcyanoacrylate nanospheres and subsequent release in human plasma in vitro, J. Microencapsul., 9, 173, 1992.
158. Maincent, P., Marchal-Heussler, L., Sirbat, D., Thouvenot, P., Hoffman, M., and Vallet, J.A., Polycaprolactone colloidal carriers for controlled ophthalmic delivery, 19th International Symphosium on Controlled Release of Bioactive Materials, 1992, 226.
159. Jalil, R. and Nixon, J.R., Microencapsulation using poly(L-lactic acid), IV. Release properties of microcapsules containing phenobarbitone, J. Microencapsul., 7, 53, 1990.
160. Su, H., Jeong, B., Rathi, R., and Kim, S.W., Regulation of smooth muscle cell proliferation using paclitaxel-loaded poly(ethylene oxide)-poly(lactide/glycolide) nanospheres, J. Biomed. Mater. Res., 42, 331, 1998.
161. Anderson, J.M. and Shive, M.S., Biodegradation and biocompatibility of PLA and PLGA microspheres, Adv. Drug Deliv. Rev., 28, 5, 1997.
162. Littenberg, R.L., Anaphylactoid reaction to human albumin microspheres, J. Nucl. Med., 16, 236, 1975.
163. Gupta, P.K., Hung, C.T., and Perrier, D.G., Albumin microspheres, II. Effect of stabilization temperature on the release of Adriamycin, Int. J. Pharm., 33, 147, 1986.
164. Gupta, P.K., Lam, F.C., and Hung, C.T., Albumin microspheres, IV. Effect of protein concentration and stabilization time on the release of Adriamycin, Int. J. Pharm., 51, 253, 1989.
165. Couvreur, P., Grislain, L., Linaerts, V., Brasseur, P., Guiot, P., and Biernacki, A., Biodegradable polymeric nanoparticles as drug carriers for antitumor agents, in Polymeric Nanoparticles as Drug Carriers for Antitumor Agents, Guiot, P. and Couvreur, P., Eds., Boca Raton, FL: CRC Press, 1986, 27.
166. Gopferich, A., Alonso, M.J., and Langer, R., Development and characterization of microencapsulated microspheres, Pharm. Res., 11, 1568, 1994.
167. Ron, E., Turek, T., Mathiowitz, E., Chasin, M., Hageman, M., and Langer, R., Controlled release of polypeptides from polyanhydrides, Proc. Natl. Acad. Sci. USA, 90, 4176, 1993.
168. Göpferich, A., Alonso, M.J., and Langer, R., Development and characterization of microencapsulated microspheres, Pharm. Res., 11(11), 1568, 1994.
169. Hausberger, A.G. and DeLuca, P.P., Characterization of biodegradable poly(D,L-lactide-co-glycolide) polymers and microspheres, J. Pharm. Biomed. Anal, 13(6), 747, 1995.
170. Jeyanthi, R., Mehta, R.C., Thanoo, B.C., and DeLuca, P.P., Effect of processing parameters on the properties of peptide-containing PLGA microspheres, J. Microencapsul., 14(2), 163, 1997.
171. Huang, L.K., Mehta, R. C., and DeLuca, P.P., Evaluation of a statistical model for the formation of poly [acryloyl hydroxyethyl starch] microspheres,Pharm. Res., 14(4), 475, 1997.
172. Jain, R., Shah, N.H., Malick, A.W., and Rhodes, C.T., Controlled drug delivery by biodegradable poly(ester) devices: Different preparative approaches, Drug Dev. Ind. Pharm., 24(8), 703, 1998.
173. Govender, T., Stolnik, S., Garnett, M.C., Illum, L., and Davis, S.S., PLGA nanoparticles prepared by nanoprecipitation: Drug loading and release studies of a water soluble drug, J Controlled Rel., 57(2), 171, 1999.
174. Fessi, H., Puisieux, F., Devissaguet, J.P., Ammoury, N., and Benita, S., Nanocapsule formation by interfacial deposition following solvent displacement, Int. J. Pharm., 55, R1, 1989.
175. Cleek, R.L., Rege, A.A., Denner, L.A., Eskin, S.G., and Mikos, A.G., Inhibition of smooth muscle cell growth in vitro by an antisense oligodeoxynucleotide released from poly(DL-lactic-co-glycolic acid) microparticles, J. Biomed. Mater. Res., 35, 525, 1997.
176. Leroux, J.C., Allemann, E., Doelker, E., and Gurny, R., New approach for the preparation of nanoparticles by an emulsification-diffusion method, Eur. J. Pharm. Biopharm., 41, 14, 1995.
177. Quintanar-Guerrero, D., Fessi, H., Allemann, E., and Doelker, E., Influence of stabilizing agents and preparative variables on the formation of poly(D,L-lactic acid) nanoparticles by an emulsification-diffusion technique, Int. J. Pharm., 143, 133, 1996.
178. Ibrahim, H., Bindschaedler, C., Doelker, E., Buri, P., and Gurny, R., Aqueous nanodispersions prepared by a salting-out process, Int. J. Pharmaceut., 87, 239, 1992.
179. Song, C.X., Labhasetwar, V., Murphy, H., Qu, X., Humphrey, W.R., Shebuski, R.J., and Levy, R.J., Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery, J. Controlled Rel., 43, 197, 1997.
180. Niwa, T., Takeuchi, H., Hino, T., Kunou, N., and Kawashima, Y., Preparation of biodegradable nanospheres of water-soluble and insoluble drugs with D,L-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method and the drug release behavior, J. Controlled Rel., 25, 89, 1993.
181. Wehrle, P., Magenheim, B., and Benita, S., The influence of process parameters on the PLA nanoparticle size distribution, evaluated by means of factorial design, Eur. J. Pharm. Biopharm., 41, 19, 1995.
182. Murakami, H., Kobayashi, M., Takeuchi, H., and Kawashima, Y., Preparation of poly(DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method, Int. J. Pharmaceut., 187, 143, 1999.
183. Zambaux, M.F., Bonneaux, F., Gref, R., Maincent, P., Dellacherie, E., Alonso, M.J., Labrude, P.,and Vigneron, C., Influence of experimental parametrs on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method, J. Controlled Rel., 50, 31, 1998.
184. O'Donnell, P.B. and W, M.J., Preparation of microspheres by the solvent evaporation technique, Adv. Drug Deliv. Rev., 28, 25, 1997.
185. O'Donnell, P.B. and McGinity, J.W., Properties of multiphase microspheres of poly(dl-lactic acid) or poly(dl-lactic-co-glycolic acid) produced by mechanical agitation, sonication, or potentiometric dispersion, J. Microencapsul., 13, 667, 1996.
186. Gorner, T., Gref, R., Michenot, D., Sommer, F., Tran, M.N., and Dellacherie, E., Lidocaine-loaded biodegradable nanospheres, I.Optimization of the drug incorporation into the polymer matrix, J. Controlled Rel., 57, 259, 1999.
187. Scholes, P.D., Coombes, A.G.A., Illum, L., Davis, S.S., Watts, J.F., Ustariz, C., Vert, M., and Davies, M.C., Detection and determination of surface levels of poloxamer and PVA surfactant on biodegradable nanospheres using SSIMS and XPS,J. Controlled Rel., 59, 261, 1999.
188. Oh, J.E., Nam, Y.S., Lee, K.H., and Park, T.G., Conjugation of drug to poly(d,l-lactic-co-glycolic acid) for controlled release from biodegradable microspheres, J. Controlled Rel., 57, 269, 1999.
189. Gonsalves, K.E., Jin, S., and Baraton, M.-I., Synthesis and surface characterization of functionalized polylactide copolymer microparticles, Biomaterials, 19, 1501, 1998.
190. Hamada, A., Ohya, Y., and Ouchi, T., Biodegradable microspheres having reactive groups preparated with poly(lactic acid-co-depsipeptide), 25 International Symposium on Controlled Release of Bioactive Materials, Las Vegas, 1998, 727.
191. Verrecchia, T., Huve, P., Bazile, D., Veillard, M., Spenlehauer, G., and Couvreur, P., Adsorption/desorption of human serum albumin at the surface of poly(lactic acid) nanoparticles prepared by a solvent evaporation process, J. Biomed. Mater. Res., 27, 1019, 1993.
192. Bazile, D., Prud'homme, C., Bassoullet, M.T., Marlard, M., Spenlehauer, G., and Veillard, M., Stealth Me.PEG-PLA nanoparticles avoide uptake by the mononuclear phagocyte system, J. Pharm. Sci., 84, 493, 1995.
193. Fishbein, I., Banai, S., Levitzki, A., Moscovitz, D., Gertz, S.D., Gazit, A., and Golomb, G., Perivascular and intraluminal delivery systems of tyrphostin for the treatment of restenosis, 23rd International Symposium on Controlled Release of Bioactive Materials, Kyoto, 1996, 17.
194. Banai, S., Wolf, Y., Golomb, G., Pearle, A., Waltenberger, J., Fishbein, I., Schneider, A., Gazit, A., Perez, L., Huber, R., Lazarovichi, G., Rabinovich, L., Levitzki, A., and Gertz, S.D., PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine, Circulation, 97, 1960, 1998.